Manufacturer
NOVARTIS FARMA S.P.A.
Contents
Diclofenac Na
Indication
Acute pain, Acute gout, Acute musculoskeletal disorders, Ankylosing spondylitis, Bursitis, Osteoarthritis, Pain after accidental trauma, Pain and inflammation associated with dental surgery, Pain and inflammation associated with minor surgery, Pain and inflammation associated with orthopaedic surgery, Pyrophosphate arthropathy, Rheumatoid arthritis, Sprains, Strains, Tendinitis, Tenosynovitis.
Instruction
Should be taken with food. Take immediately after meals.
Drug interaction
Increased risk of gastrointestinal ulceration, perforation or haemorrhage with other corticosteroids, SSRIs. Increased risk CV-related adverse reactions with cardiac glycosides. Increased risk of hyperkalaemia and renal toxicity with ACE inhibitors, diuretics, ciclosporin, tacrolimus. Increased risk of haematological toxicity with zidovudine. Increased levels and risk of toxicity with digoxin, lithium, methotrexate, pemetrexed, phenytoin. Decreased effect with colestipol, cholestyramine. Decrease effect of mifepristone. Increased peak plasma concentration with CYP2C9 inhibitors e.g. voriconazole. Potentially Fatal: Increased risk of gastrointestinal ulceration, perforation or haemorrhage with other NSAIDs (e.g. aspirin), antiplatelets, anticoagulants (e.g. warfarin).
Malaysia
